Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) has issued an announcement.
Fuso Pharmaceutical Industries reported a 2.9% increase in net sales to ¥62.3 billion for the year ended March 31, 2026, but operating and ordinary profits fell 36.1% and 37.9%, respectively, as margins contracted. Despite this, the company swung from a prior-year loss to a profit of ¥2.0 billion, improved net assets to ¥35.1 billion, and raised its annual dividend to ¥90 per share, signaling a continued focus on shareholder returns.
The company forecasts modest sales growth to ¥63.2 billion in the fiscal year ending March 31, 2027, while projecting further declines in profit as operating and ordinary income are expected to drop more than 20%. Cash flows from operating activities turned negative and equity ratio slipped to 38.8%, underscoring earnings and balance sheet pressures even as management maintains dividend levels and prepares detailed disclosures and briefings for investors and the press.
More about Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. is a Japan-based drug manufacturer listed on the Tokyo Stock Exchange, operating under Japanese GAAP. The company focuses on pharmaceutical products and related healthcare offerings, generating the bulk of its revenue from domestic net sales of prescription and medical-use drugs.
Average Trading Volume: 31,458
Technical Sentiment Signal: Hold
Current Market Cap: Yen19.28B
Learn more about 4538 stock on TipRanks’ Stock Analysis page.